Short-sellers target Bavarian Nordic and its cancer vaccine candidate

As it works to bring its prostate cancer vaccine Prostvac to market and expand its smallpox vaccine business, Danish vaccine maker Bavarian Nordic encountered a new set of challenges this week. Despite a billion-dollar partnership with Bristol-Myers Squibb ($BMY), it's the target of a short-selling campaign. New York City-based hedge fund Kerrisdale Capital initiated its crusade against the Danish company and publicly predicted Bavarian Nordic's prostate cancer vaccine candidate will fail its ongoing Phase III trial. The fund's manager, Sahm Adrangi, said a "misleading statistical fluke" in previous trials will lead to the vaccine's troubles, adding that cancer vaccines have seen two decades of "unmitigated failure" and the fund expects "nothing different from Bavarian Nordic." More from FierceVaccines

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.